By David WinningSYDNEY--CSL Ltd., Australia's largest pharmaceutical company, said it had signed initial deals for the supply of vaccines against the novel coronavirus if they successfully complete clinical trials. CSL said a heads of agreement with the Australian government covers 51 million doses of a vaccine being developed by the University of Queensland. Production of the vaccine to support late-stage clinical trials is underway at CSL's biotech manufacturing facilities in Broadmeadows, a suburb of Melbourne. CSL said results from pre-clinical and early clinical studies for the vaccine, known as UQ-CSL V451, are promising. The University of Queensland is currently undertaking a Phase 1 clinical study to assess the vaccine candidate's safety and immunogenicity in healthy volunteers.

Source: Wall Street Journal September 06, 2020 22:30 UTC